Big pharma blurring the lines with big biotech

CHAL 21

Steve Vieux, svieux@ftc.gov, Health Care Seveices and Products Division, U.S. Federal Trade Commission, 600 Pennsylvania Avenue, NW, Washington, DC 20580
An update on antitrust issues effecting biologics. This presentation will discuss the recent developments with pharma companies been branching into biologics through joint ventures, mergers, or organic growth.
 

Pharmaceutical Companies Dealing with The Intersection of Patents and Anti-Trust Issues
10:00 AM-12:00 PM, Tuesday, April 8, 2008 Morial Convention Center -- Rm. 243, Oral

Division of Chemistry & the Law

The 235th ACS National Meeting, New Orleans, LA, April 6-10, 2008